Circulating Tumor Cells in Breast Cancer Patients: An Evolving Role in Patient Prognosis and Disease Progression
2011

Circulating Tumor Cells in Breast Cancer Patients

Sample size: 177 publication Evidence: moderate

Author Information

Author(s): Holly Graves, Brian J. Czerniecki

Primary Institution: Hospital of the University of Pennsylvania

Hypothesis

What is the role of circulating tumor cells (CTCs) in breast cancer prognosis and disease progression?

Conclusion

Circulating tumor cells are a poor prognostic marker in metastatic breast cancer and may also indicate a poorer prognosis in early breast cancer.

Supporting Evidence

  • CTCs are found in the blood of breast cancer patients but not in those with benign disease.
  • Presence of CTCs is associated with poorer prognosis in both early and metastatic breast cancer.
  • Studies suggest that CTC levels may guide changes in therapy.

Takeaway

Doctors are studying tiny cancer cells that float in the blood to see if they can help predict how bad breast cancer will be.

Methodology

The study reviews various methodologies for detecting circulating tumor cells and their prognostic implications in breast cancer.

Limitations

The study primarily focuses on the prognostic role of CTCs and may not cover all aspects of breast cancer treatment.

Participant Demographics

The study includes breast cancer patients, with a focus on both early and metastatic stages.

Digital Object Identifier (DOI)

10.4061/2011/621090

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication